Structural Biology of Cell Signalling

Dr Sebastian Guettler’s group is researching the ways in which certain enzymes, known as ADP-ribosyltransferases (ARTs), control cell function.

Professor Sebastian Guettler

Deputy Head of Division:

Structural Biology of Cell Signalling

Professor Sebastian Guettler is Deputy Head of the Division of Structural Biology. He studies the precise molecular mechanisms of signalling processes central to cancer stem cell function, with a particular interest in Wnt/β-catenin signalling, telomere length homeostasis and their regulation by ADP-ribosylation. He has a long-standing interest in understanding tankyrase, a poly-ADP-ribosyltransferase with roles in both Wnt/β-catenin signalling and telomere maintenance.

Researchers in this group

I graduated from the University of Southampton, with an integrated Master’s in Biochemistry (MSc). For my bachelor’s project, I investigated the effects of reactive oxygen species and vitamin C on S100A9 aggregation in Alzheimer’s disease. For my Master’s project, I investigated the functional importance of Snap29 for mitosis in Drosophila. For my PhD, I study the molecular mechanisms of telomere maintenance.

Ben Broadway .

Email: [email protected]

Location: SuttonChelsea

I graduated from the University of Manchester, with a BSc in Biochemistry with industrial experience (IE). I spent my IE at Mayo Clinic in Jacksonville, Florida, investigating mitochondrial dysfunction in disease. In 2020, I joined the ICR to study how tankyrase regulates Wnt/β-catenin signalling utilising genetic techniques.

.

Email: [email protected]

Location: Chelsea

I joined Sebastian's lab in August 2023 as a Postdoctoral Fellow to investigate the molecular mechanisms of the Wnt/β-catenin signalling pathway in normal and cancer cells. Prior to joining the ICR, I was a Postdoctoral Research Fellow at the laboratory of Dr Roger Grand at the University of Birmingham, where I also obtained my PhD studying the DNA damage response. My PhD research focussed on the role of CCR4-NOT complex in the DNA damage response (DDR), and how disruption of this complex contributes to transcription-mediated genome instability. My current research mainly focusses on understanding the mechanisms of the β-catenin destruction complex.

Oviya Inian .

Email: [email protected]

Location: Chelsea

Oviya studied Biotechnology during her undergraduate degree at SRM University, India. She then completed her PhD in Professor Sara Sandin's lab at Nanyang Technological University, Singapore. Oviya joined the ICR as a postdoc in 2019 and is currently studying the function of tankyrase at telomeres.

Headshot of Katy Miller .

Phone: +44 20 3437 6201

Email: [email protected]

Location: Chelsea

Katy joined the ICR in October 2023 as a PhD student. She previously completed an MChem at Durham University, where her research focused on novel therapeutics for Alzheimer's disease. At the ICR she is working on a collaborative project with Professor Guettler and Professor Hoelder, developing tankyrase-directed PROTACs as novel scaffolding inhibitors.

.

Email: [email protected]

Location: Chelsea

I completed my B.Tech in Chemical Engineering from Anna University in Chennai, India, in 2013. Following my interest in sustainable bioenergy, I pursued an MRes in Sustainable Bioenergy at the School of Biosciences, University of Nottingham, UK, from 2014 to 2016. During my time there, I had the opportunity to intern at the Flow Cytometry Facility based in Queens Medical Centre in Nottingham, which inspired me to pursue higher research studies in basic science. Motivated by my newfound passion, I embarked on a PhD in the prestigious Max Planck Research Group, based at the Malopolska Centre of Biotechnology in Krakow, Poland. My doctoral research focussed on unravelling the mysteries of an ancient ubiquitin-like protein (Urm1) conjugation mechanism called urmylation. To investigate its function, I employed crystallography, mass spectrometry, and biochemical assays, successfully deciphering the intricate workings of urmylation. In May 2023, I joined the Guettler lab to study the molecular mechanisms of the Wnt/β-catenin signalling pathway.

Saira Sakalas .

Email: [email protected]

Location: Sutton

During my bachelor's degree at Erasmus University College, I completed a summer internship at Karolinska Institute in the field of cancer biology. I continued with my studies at Imperial College London in Molecular Basis of Human Disease. Here at the ICR, I am studying the molecular mechanisms of Wnt/beta-catenin signalling.

.

Email: [email protected]

Location: Chelsea

Professor Sebastian Guettler's group have written 29 publications

Most recent new publication 4/2025

See all their publications

Research, projects and publications in this group

ADP-ribosylation is a post-translational modification carried out by ADP-ribosyltransferases (ARTs), which transfer ADP-ribose from NAD+ onto substrates. ADP-ribosylation controls many aspects of cell function, including DNA repair, cell division, telomere maintenance, chromatin dynamics, apoptosis and various signal transduction processes. Given their roles in DNA repair, telomere homeostasis and cancer-relevant signalling pathways, several ARTs are being explored as potential cancer therapy targets.

In humans, the family of intracellular ARTs encompasses 17 members with similar catalytic domains but greatly diverse non-catalytic accessory domains. Different catalytically active ARTs can either transfer a single unit of ADP-ribose or attach ADP-ribose processively, thereby constructing poly(ADP-ribose) (PAR) chains, which can be of varying length and structure. Enzymes in the latter group are known as poly(ADP-ribose)polymerases (PARPs). Compared to other types of post-translational modification, such as phosphorylation, PARylation remains understudied.

We take a particular interest in the PARP enzyme tankyrase, which fulfils a wide range of biological functions, many of which are relevant to cancer. The human genome encodes two highly similar tankyrase paralogues, TNKS and TNKS2. Both share a C-terminal catalytic PARP domain, a set of five N-terminal ankyrin repeat clusters (ARCs) responsible for substrate recruitment, and a polymerising sterile alpha motif (SAM) domain in between.

Our previous structure-function work has revealed the mechanisms of substrate recognition and polymerisation by tankyrase and shown that tankyrase can act as a scaffolding protein, independently of its catalytic function. We now aim to use both X-ray crystallography and cryo-electron microscopy to understand how tankyrase’s various domains act together. Moreover, we work with chemists to develop novel approaches to modulate tankyrase function.

Sebastian Guettler Tankyrase diagram showing how it uses its ankyrin repeat clusters (ARCs) to recruit binding partners

Tankyrase (TNKS, TNKS2) uses its ankyrin repeat clusters (ARCs) to recruit binding partners, many of which are also PARylated by tankyrase’s PARP domain. ARCs recognise degenerate peptide motifs found in many proteins. Our earlier work (Guettler et al., 2011) has revealed the substrate recognition mechanism and explained how the rare human disease Cherubism is caused. The sterile alpha motif (SAM) domain enables tankyrase polymerisation. We have revealed the mechanism of tankyrase polymerisation and shown that both ARCs and the SAM domain polymer fulfil essential scaffolding roles and are required for efficient substrate modification (Mariotti et al., 2016). (Images modified from Guettler et al., 2011; Mariotti et al., 2016 and Pollock et al., 2017)

Molecular mechanisms of Wnt/beta-catenin signalling, telomere maintenance and their regulation by poly(ADP-ribosyl)ation

In a series of projects, we take a reductionist approach to study how large macromolecular complexes coordinate Wnt/beta-catenin signalling and telomere length homeostasis and how they are controlled by tankyrase-dependent poly(ADP-ribosyl)ation. We combine biochemical assays with cryo-electron microscopy and X-ray crystallography to uncover the detailed mechanisms governing the functions of these complexes and their regulation.

Besides uncovering fundamental mechanisms underlying stem and cancer cell function, we endeavour to understand the molecular basis of disease mutations and open up new opportunities for pharmacological intervention.

Sebastian Guettler Wnt beta catenin signalling

Wnt/beta-catenin signalling revolves around controlling the levels of the transcriptional co-activator beta-catenin. A multi-protein beta-catenin destruction complex captures cytoplasmic beta-catenin and limits its abundance by initiating its phosphorylation- and ubiquitination-dependent degradation. Notably, destruction complex function is impaired in the vast majority of colorectal cancer cases. Wnt stimulation remodels the destruction complex into a membrane-localised “Wnt signalosome” incapable of destabilising beta-catenin. Tankyrase controls the receptiveness of cells to incoming Wnt signals by PARylating AXIN, thereby destabilising the destruction complex or promoting Wnt signalosome formation. (Images modified from Mariotti et al., 2017)

A small number of key signalling pathways collaborate to confer stem-cell properties to cells, and the Wnt/beta-catenin pathway is a prototypic example for such a pathway. Wnt/beta-catenin signalling plays important roles in embryonic development and adult organ homeostasis. It is dysregulated in a number of different cancer types, most prominently in colorectal cancers, the vast majority of which bear mutations in components of the pathway.

At the same time, stem and most cancer cells rely on active telomerase to prevent erosion of their telomeres and maintain their unlimited replicative potential. Recent findings show that Wnt/beta-catenin signalling and telomere homeostasis are closely intertwined at multiple levels and form an integrated self-renewal programme, relevant to normal tissue regeneration, ageing and cancer.

The poly(ADP-ribose)polymerase (PARP) tankyrase both promotes Wnt/beta-catenin signalling and is essential for normal telomere extension in humans, thereby providing an important link between both processes.

Our overarching goal is to understand the precise molecular mechanisms that underlie Wnt/beta-catenin signalling, telomere maintenance and their control by poly(ADP-ribosyl)ation. We have a long-standing interest in deciphering the structural basis and molecular mechanisms of tankyrase function.

We employ biochemistry, structural biology and cell biology to study the molecular mechanisms of Wnt/beta-catenin signalling and telomere homeostasis, with a particular focus on how poly(ADP-ribosyl)ation (PARylation) controls both processes. Besides understanding fundamental mechanisms of cell function, we aim to uncover novel potential therapeutic avenues in cancer.

A Venn diagram showcasing interdependence between Poly(ADP-ribosyl)ation, Wnt/B-Catenin Signalling and Telomere Maintenance alongside Biochemistry, Biophysics, Structural Biology, and Cell Biology.

We take a multidisciplinary approach to study Wnt/beta-catenin signalling, telomere maintenance and their regulation by poly(ADP-ribosyl)ation. Structural biology is at the centre of our work. (Images modified from Mariotti et al., 2016)

Vacancies at the ICR

Working at the ICR

Health Economist

  • Chelsea
  • Convergence Science Centre Scientific
  • £50,825 - £61,525 per annum
  • Fixed term

Under the guidance of Cancer Technology Catalyst team lead Dr Patrick Kierkegaard, we are seeking to recruit a Health Economist to pioneer evaluations at the CRUK Convergence Science Centre. Based in South Kensington, London, with travel to partner sites (The Royal Marsden NHS Foundation Trust, ICR Sutton, Imperial College Healthcare NHS Trust). The successful candidate will lead early-stage health economic modelling and health technology assessment (HTA) for cutting-edge oncology innovations, including precision drugs, diagnostics, treatments, clinical guidelines, and digital health technologies (DHTs). Department/Directorate Information The Cancer Research UK Convergence Science Centre (CSC) is a partnership between Imperial College London and The Institute of Cancer Research (ICR) with funding from Cancer Research UK. Convergence research is driven by a societal need and utilises a deep integration across disciplines. Professor Axel Behrens is the Scientific Director of the CRUK Convergence Science Centre. This position of Health Economist is integrated within our Cancer Technology Catalyst team (CTC). The CTC is an initiative designed to expedite the journey of promising cancer technologies from concept to clinical impact. Led by a diverse team of experts, the CTC is committed to unlocking the full potential of innovative solutions and addressing the challenges inherent in bringing them to patients. By harnessing a collaborative Team Science approach, the CTC works closely with Principal Investigators and their teams to develop comprehensive evidence packages that not only inform robust value propositions for cancer technologies, but also strategically position them for successful clinical integration. About you Please see the attached job description for essential skills and qualifications for this role, and further information. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Patrick Kierkegaard via [email protected].

Trial Statistician / Senior Trial Statistician

  • Sutton
  • Clinical Trials and Statistics Unit
  • £38,891 - £46,806 OR £47,634 - £52,324
  • Fixed term

The Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU) is recruiting to its statistical team. We want to hear from you if you: • Like the challenge of analysing clinical trial datasets and want to become part of a statistical team that is dedicated to translating cutting-edge science into quality clinical trials that can transform cancer care • Want variety in your work and opportunities to apply and broaden your statistical knowledge across a number of therapeutic areas in oncology • Like to work as part of a multi-disciplinary research team with like-minded statisticians, clinical investigators, translational analysts, bioinformaticians, and trial managers. Applications are now open for a Trial Statistician/Senior Trial Statistician position to join our team of over 20 Statisticians. This post offers an excellent opportunity for an enthusiastic and well-motivated Statistician to work in a dynamic and supportive academic environment at one of the leading UK cancer trials units. Key Requirements The successful applicant will have a post-graduate qualification in statistics or an allied field (or a first degree in statistics along with practical experience in medical statistics). Additionally, they should demonstrate a solid understanding of clinical trials and experience in applying statistical methods to real-world data. Effective oral and written communication skills and enthusiasm for collaborating with researchers from different disciplines are essential. Department/Directorate Information ICR-CTSU manages an exciting portfolio of national and international phase II and III clinical trials and an expanding number of early phase I/II cancer trials. You will work as part of a multi-disciplinary team on the statistical development, oversight and analysis of a number of clinical trials within ICR-CTSU’s portfolio and the ICR/Royal Marsden Drug Development Unit’s early phase trials portfolio as well as on associated trials methodology research and translational biomarker research studies. We encourage all applicants to access the job pack attached for more detailed information regarding this role. This is an office-based role. Requests for hybrid working (splitting time between our Sutton site and home) may be considered following successful completion of the probation period/key training and if the role allows. Flexible working options may be considered. For informal discussion about the Trial Statistician/Senior Trial Statistician post, please contact Lucy Kilburn (Principal Statistician), email: [email protected] For general queries about the recruitment process, please contact ICR-CTSU, email: [email protected].

Industrial partnership opportunities with this group

Opportunity: Biomarker for CDK4/6 and/or aromatase inhibitor response in breast cancers

Commissioner: Dr Maggie Cheang

Recent discoveries from this group

Using cryo-electron microscopy, researchers obtained a detailed map (shown in orange) of the chain-like tankyrase structure.

23/11/22

Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.
PhD student Iona Black in the lab

28/08/20

As our #KickstartICR appeal draws to a close, we spoke to PhD student Iona Black about her research and the importance of fundraising for cancer research.
A scientist at work

11/12/17

We've selected our top 10 discoveries of 2016/17 – chosen because they best represent the breadth of our research and our ambitions set out in our research strategy.
ICR Logo

22/06/17

Dr Sebastian Guettler, a Team Leader at The Institute of Cancer Research, London, has been recognised as one of the most promising young biomedical researchers in the UK and awarded a Lister Institute Research Prize Fellowship.